| NET LOSS PER SHARE |
NET LOSS PER SHARE
Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted earnings per share (“EPS”) calculations for the periods ended:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
| ($ in thousands, except share and per share amounts) |
2023 |
|
2022 |
|
2023 |
|
2022 |
| Numerator: |
|
|
|
|
|
|
|
| Net loss |
$ |
(19,499) |
|
|
$ |
(10,790) |
|
|
$ |
(37,989) |
|
|
$ |
(22,362) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss attributable to common stockholders |
$ |
(19,499) |
|
|
$ |
(10,790) |
|
|
$ |
(37,989) |
|
|
$ |
(22,362) |
|
| Denominator: |
|
|
|
|
|
|
|
| Weighted average common shares outstanding |
|
|
|
|
|
|
|
| Basic and diluted (in number) |
79,849,299 |
|
|
76,239,989 |
|
|
78,196,201 |
|
|
75,146,201 |
|
|
|
|
|
|
|
|
|
| Net loss per share |
|
|
|
|
|
|
|
| Basic and diluted |
$ |
(0.24) |
|
|
$ |
(0.14) |
|
|
$ |
(0.49) |
|
|
$ |
(0.30) |
|
|
|
|
|
|
|
|
|
The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
| (Number of shares) |
June 30, |
|
June 30, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
| Common stock issued under the backstop agreement |
9,600,031 |
|
|
9,600,031 |
|
|
9,600,031 |
|
|
9,600,031 |
|
| Grants of restricted stock units |
6,049,919 |
|
|
3,441,651 |
|
|
5,332,210 |
|
|
3,275,885 |
|
| Private placement warrants |
272,779 |
|
|
272,779 |
|
|
272,779 |
|
|
272,779 |
|
|